Buccal spray insulin (Oralgen) for type 2 diabetes: What evidence?

Expert Opinion on Biological Therapy

Volumn 12, Issue 6, 2012, Pages 767-772

  Palermo, Andrea ^a   Maddaloni, Ernesto ^a   Pozzilli, Paolo ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Buccal spray insulin; Hypoglycemia; Impaired glucose tolerance; Oralgen; Postprandial hyperglycemia; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE PLUS METFORMIN; GLUCOSE; INSULIN; ORALGEN; PLACEBO; UNCLASSIFIED DRUG;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE PERSONNEL; HUMAN; HYPOGLYCEMIA; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PHARMACODYNAMICS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE;

ABSORPTION; ADMINISTRATION, BUCCAL; AEROSOLS; ANIMALS; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MEDICATION ADHERENCE; MOUTH MUCOSA; TREATMENT OUTCOME;

EID: 84861305773     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.675324     Document Type: Review

References (27)

1. International Diabetes Federation Guideline Development Committee. Guideline for Management of Postmeal Glucose. International Diabetes Federation; Brussels, Belgium: 2007
2. Pozzilli P, Leslie RD, Chan J, et al. The A1C and ABCD of glycemia management in type 2 diabetes: A physician's personalized approach. Diabetes Metab Res Rev 2010;26:239-244
3. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997;20:292-298
4. Royle P, Waugh N, McAuley L, et al. Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev 2004;3:CD003890
5. Heinemann L. New ways of insulin delivery. Int J Clin Pract Suppl 2010;(166):41-6
6. Bernstein G. Delivery of insulin to the buccal mucosa utilizing the RapidMist system. Expert Opin Drug Deliv 2008 Sep;5(9):1047-1055
7. Generex Biotechnology Corp. Data on File. 2008
8. Cernea S, Kidron M, Wohlgelernter J, et al. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin Ther 2004;26:2084-2209
9. Cernea S, Kidron M, Wohlgelerenter J, et al. Dose-response relationship of oral insulin spray in healthy subjects. Diabetes Care 2005;28:1353-1357
10. Pozzilli P, Manfrini S, Costanza F, et al. Biokinetics of buccal spray insulin in patients with type 1 diabetes. Metabolism 2005;54:930-934
11. Cernea S, Kidron M, Wohlgelernter J, et al. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: A single-center, randomized, single-blind, 5-way crossover study. Clin Ther 2005;27:1562-1570
12. Lutz H, Yves J. Oral Insulin and buccal insulin: A critical reappraisal. J Diabetes Sci Technol 2009;3:568-584
13. Guevara-Aguirre J, Guevara M, Saavedra J, et al. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents. Diabetes Technol Ther 2004;6:1-8
14. Guevara-Aguirre J, Guevara M, Saavedra J, et al. Oral spray insulin in treatment of type 2 diabetes: A comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study. Diabetes Metab Res Rev 2004;20:472-478
15. Palermo A, Napoli N, Manfrini S, et al. Buccal spray insulin in subjects with impaired glucose tolerance: The prevoral study. Diabetes Obes Metab 2011;13:42-6
16. Bernstein G. Delivery of insulin to the buccal mucosa utilizing the RapidMist system. Expert Opin Drug Deliv 2008;5:1047-1055
17. Palermo A, Napoli N, Maddaloni E, et al. Buccal spray insulin for the treatment of impaired glucose tolerance. IDF 2011;DU-0374
18. Tuomilento J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350
19. Zambanini A, Feher MD. Needle phobia in type 1 diabetes mellitus. Diabet Med 1997;14:321-323
20. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(Suppl 3):S18-24
21. Okazaki K, Goto M, Yamamoto T, et al. Barriers and facilitators in relation to starting insulin therapy in type 2 diabetes. Diabetes 2008;48(Suppl):A1394
22. Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem. Diabetes Care 2005;28:2543-2545
23. Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trail Research Group. Acarbose for prevention of DM2: STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077
24. Gerstein HC, Yusuf S, Bosch J, et al. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of Rosiglitazone on frequency of DM in IGT or IFG The dream trial investigators. Lancet 2006;368:1096-1105
25. DeFronzo RA, Tripathy D, Schwenke DC, et al. ACT NOW Study. Pioglitazone for Diabetes prevention in IGT. N Engl J Med 2011;364:1104-1115
26. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care. Diabetes Care 2007;30:753-759
27. Bell DS, O'Keefe JH, Jellinger P. Postprandial dysmetabolism: The missing link between diabetes and cardiovascular events? Endocr Pract 2008;14:112-124